Case report of long-term successful use of maintenance therapy with PARP inhibitors in the primary treatment of advanced BRCA-associated ovarian cancer
Автор: Churuksaeva O.N., Kolomiets L.A., Villert A.B.
Журнал: Сибирский онкологический журнал @siboncoj
Рубрика: Случай из клинической практики
Статья в выпуске: 4 т.22, 2023 года.
Бесплатный доступ
Background. Ovarian cancer is the third most common cancer of the female reproductive system after cervical and uterine cancer and is diagnosed at stage III-IV in 2 out of 3 cases. Maintenance therapy with PARP inhibitors significantly prolongs disease-free and overall survival. The purpose of the study was to demonstrate long-term remission in a patient with advanced ovarian cancer using maintenance therapy with PARP inhibitors (olaparib). Description of the clinical case. A 54-year-old female patient with verified stage IV ovarian cancer, peritoneal carcinomatosis and left-sided pleurisy received combined modality treatment, including 2 courses of neoadjuvant chemotherapy with paclitaxel/carboplatin, cytoreductive surgery and 6 courses of postoperative chemotherapy with docetaxel/cisplatin. The patient was diagnosed with a somatic BRCA2 gene mutation (c.3708delA), which was detected by tumor DNA sequencing. The patient received maintenance therapy with olaparib for 38 months, resulting in no evidence of disease progression. Conclusion. This clinical case demonstrates the feasibility of using maintenance therapy with PARP inhibitors in a patient with initially disseminated platinum-sensitive ovarian cancer. Olaparib maintenance therapy provides stable long-term remission with no signs of adverse events and determined effect on quality of life of the patient.
Brca-мутация, ингибиторы parp
Короткий адрес: https://sciup.org/140302017
IDR: 140302017 | DOI: 10.21294/1814-4861-2023-22-4-135-141